Open AccessEffects of Vitamin D Supplementation on Plasma Aldosterone and Renin—A Randomized Placebo‐Controlled Trial
Author(s) -
Grübler Martin R.,
Gaksch Martin,
Kienreich Katharina,
Verheyen Nicolas,
Schmid Johannes,
Ó Hartaigh Bríain W. J.,
Richtig Georg,
Scharnagl Hubert,
Meinitzer Andreas,
Pieske Burkert,
FahrleitnerPammer Astrid,
März Winfried,
Tomaschitz Andreas,
Pilz Stefan
Publication year - 2016
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12825
Subject(s) - medicine , aldosterone , vitamin d and neurology , placebo , randomized controlled trial , plasma renin activity , vitamin , endocrinology , gastroenterology , blood pressure , renin–angiotensin system , alternative medicine , pathology
Increasing evidence describes a possible interplay between vitamin D insufficiency with increased aldosterone. The authors sought to evaluate the effect of vitamin D supplementation on plasma aldosterone concentration ( PAC ) in patients with hypertension and 25‐hydroxyvitamin D[25( OH )D] insufficiency. The Styrian Vitamin D Hypertension Trial was a single‐center, double‐blind, placebo‐controlled randomized clinical trial conducted from 2011 to 2014. Two hundred patients with arterial hypertension and 25( OH )D levels <30 ng/mL were enrolled. Study participants were randomized to receive either 2800 IU of vitamin D3 or placebo. The present investigation is a post hoc analysis using analysis of covariance adjusting for baseline differences. A total of 188 participants (mean±standard deviation age, 60.1±11.3 years; 47% women; 25( OH )D, 21.2±5.6 ng/mL) completed the trial. Mean differences between baseline and follow‐up PAC in the control and intervention arm were +3.3 ng/dL and +0.9 ng/dL, respectively ( P =.04). The findings indicate that vitamin D3 supplementation significantly decreases PAC in patients with arterial hypertension and 25( OH )D insufficiency.